During the past decade, Ch Avignon conducted 108 clinical trials. In the 10-year time frame, 108 clinical trials started and 4 clinical trials were completed, i.e. on average, 3.7% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 2 clinical trials were completed. i.e. 4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ch Avignon" #1 sponsor was "The Lymphoma Academic Research Organisation" with 18 trials, followed by "Federation Francophone de Cancerologie Digestive" with 14 trials sponsored, "Groupe Francophone des Myelodysplasies" with 14 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 9 trials sponsored and "French Innovative Leukemia Organisation" with 9 trials sponsored. Other sponsors include 113 different institutions and companies that sponsored additional 66 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ch Avignon" #1 collaborator was "Acute Leukemia French Association" with 4 trials as a collaborator, "Janssen-Cilag Ltd." with 4 trials as a collaborator, "Ministry of Health, France" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 3 trials as a collaborator. Other collaborators include 95 different institutions and companies that were collaborators in the rest 91 trials.

According to Clinical.Site data, the most researched conditions in "Ch Avignon" are "Colorectal Cancer" (10 trials), "Multiple Myeloma" (9 trials), "Myelodysplastic Syndromes" (9 trials), "Pancreatic Cancer" (6 trials) and "Acute Myeloid Leukemia" (5 trials). Many other conditions were trialed in "Ch Avignon" in a lesser frequency.

Most popular intervention types in "Ch Avignon" are "Drug" (103 trials), "Other" (28 trials), "Procedure" (23 trials), "Device" (17 trials) and "Biological" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Rituximab" (6 trials), "fluorouracil" (6 trials), "leucovorin calcium" (6 trials) and "Azacitidine" (5 trials). Other intervention names were less common.

The vast majority of trials in "Ch Avignon" are 174 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Ch Avignon". 4 are not yet recruiting, 38 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 92 completed trials in Ch Avignon, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Ch Avignon, 4 "Phase 1" clinical trials were conducted, 57 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 36 trials that are defined as “Not Applicable".

Ch Avignon has several departments that took part in Clinical trials: "Service de cardiologie, CH Avignon" - 2 trials